This inventor holds 38 USPTO granted patents and 9 published patent applications, plus 5 CIPO patents and 15 EPO patents, primarily in Kinase Inhibitors. Top assignees: Vertex Pharmaceuticals, Inc., Janssen Pharmaceutica Nv, Merck Patent Gmbh. Active years: 2012-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Rouen, FR (2012 - 2014)
- Ramsgate, GB (2012 - 2017)
- Kent, GB (2014 - 2023)
- Abingdon, GB (2014 - 2024)
Company Filing History:
27 out of 1,167 
11 out of 2,101 
3 out of 3,022 
Years Active: 2012-2025
Areas of Expertise:
Title: Pierre-Henri Storck: Innovator in Pharmaceutical Compounds
Introduction
Pierre-Henri Storck is a distinguished inventor based in Abingdon, GB, known for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio totaling 27 patents, he has made strides in developing compounds that target critical biological pathways.
Latest Patents
Among his latest patents are notable inventions such as "Compounds useful as inhibitors of ATR kinase." This invention encompasses a range of compounds designed to inhibit ATR protein kinase, along with various pharmaceutically acceptable compositions. The invention not only details the methods for treating diverse diseases, disorders, and conditions but also outlines processes for the preparation of these compounds and their intermediates. Additionally, his patent titled "GCN2 inhibitors and uses thereof" presents compounds and compositions focused on GCN2 inhibition and their therapeutic applications.
Career Highlights
Pierre-Henri has built his career at prominent companies, including Vertex Pharmaceuticals and Merck Patent GmbH. His work at these institutions has propelled pharmaceutical research and created pathways for novel therapies that impact numerous medical fields.
Collaborations
Throughout his career, Pierre-Henri has collaborated with esteemed colleagues including Jean-Damien Charrier and Joanne Louise Pinder. Together, they have contributed to advancing the understanding and application of kinase inhibitors in scientific research and therapeutic contexts.
Conclusion
With a robust patent portfolio and collaborative spirit, Pierre-Henri Storck illustrates the epitome of innovation in the pharmaceutical industry. His dedication to creating beneficial compounds continues to support advancements in medical treatments and research methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile